We have used an anti-CD7 antibody drug conjugate (ADC) to show that the binding of antibody to surface CD7 protein results in rapid internalization of the antigen together with the ADC. As a consequence, cell killing was observed via induction of apoptosis and …

2023年11月2日 · The Fc-optimized ADC, CD7-DE-vcMMAE, as well as the unconjugated antibody, CD7-DE, showed improved binding to activating Fcγ receptors (FcγRIIa, FcγRIIIa) compared to a CD7 antibody lacking the DE-modification.

2024年11月5日 · BVX001 is a First-in-Class anti-CD33 x anti-CD7 bispecific antibody-drug conjugate (ADC) using auristatin MMAF as its payload. We present data on its favorable safety profile and compelling efficacy in two relevant pre-clinical models of the disease.

2024年1月15日 · In this study, a novel anti-CD7 antibody-drug conjugate (ADC, J87-Dxd) was successfully generated and used for T-ALL treatment. Firstly, to obtain anti-CD7 mAbs, we expressed and purified the CD7 protein extracellular domain. Utilizing hybridoma technology, we obtained three anti-CD7 mAbs (J87, G73 and A15) with a high affinity for CD7.

2022年8月22日 · 除了car-t和car-nk形式，cd7有adc形式药物进入临床。 T-Guard是anti-CD7×RTA的ADC+anti-CD3×RTA的ADC联合用药，现已进入Ⅲ期临床，是现在CD7靶点的药物的最高研究阶段，但由于安全问题暂被撤回。

Here, we generated a novel anti-CD7 ADC (J87-Dxd) with an anti-CD7 mAb (J87), a topoisomerase I inhibitor (Deruxtecan, DXd) and a cleavable maleimide-GGFG peptide linker. Moreover, we demonstrated its potent antitumor activity against CD7-expressing T-ALL cells both in vitro and in vivo.

2024年1月15日 · Here, we generated a novel anti-CD7 ADC (J87-Dxd) with an anti-CD7 mAb (J87), a topoisomerase I inhibitor (Deruxtecan, DXd) and a cleavable maleimide-GGFG peptide linker. Moreover, we demonstrated its potent antitumor activity against CD7-expressing T-ALL cells both in vitro and in vivo.

gomes-silva等 研究结果发现，经过基因编辑的cd7 ko-car-t(cd7 ko)可以有效清除cd7 ＋ aml肿瘤细胞株、患者cd7 ＋ aml原代肿瘤细胞及其克隆后代，与此同时，cd7 ko-t在体内并不影响髓系细胞、红系祖细胞等细胞增殖分化；在异种动物模型实验中，cd7 ko-t可使cd7 ＋ aml肿瘤 ...

2022年8月22日 · 除了car-t和car-nk形式，cd7有adc形式药物进入临床。 T-Guard是anti-CD7×RTA的ADC+anti-CD3×RTA的ADC联合用药，现已进入Ⅲ期临床，是现在CD7靶点的药物的最高研究阶段，但由于安全问题暂被撤回。

We have used an anti-CD7 antibody drug conjugate (ADC) to show that the binding of antibody to surface CD7 protein results in rapid internalization of the antigen together with the ADC. As a consequence, cell killing was observed via induction of apoptosis and …